Appili Therapeutics Inc has been in the spotlight recently as it navigates significant operational updates and market challenges.
This week, Appili Therapeutics Inc (APLI.TO) has seen its stock remain steady at C$0.01, with no significant price movement over the past week. The company recently announced its fiscal year 2026 financial and operational results, which have drawn attention but not led to any immediate price changes. Investors are keeping a close eye on the developments as they consider the company's future prospects.
Investor takeaway: For investors in Appili Therapeutics, the recent announcements highlight the company’s ongoing focus on its vaccine programs, particularly the receipt of a substantial funding award from NIAID, which could bolster its financial position and operational capabilities.
Advertisement
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+50.00%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 900.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+900.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
292.8%
Annualized
90-Day Vol
261.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.01 – C$0.04 |
| 60 trading days | C$0.01 | C$0.00 – C$0.06 |
| 90 trading days | C$0.01 | C$0.00 – C$0.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Market cap at C$1.99 million reflects investor caution.
With a market cap of just C$1.99 million, investors may be wary of the company's ability to sustain growth and profitability amidst substantial losses and a high negative return on equity.
Bull case
The company has secured a US$40 million award from the National Institute of Allergy and Infectious Diseases (NIAID) to support its VXV-01 vaccine program. This funding could enhance its operational growth and market presence.
Bear case
Despite the funding and operational progress, Appili's stock has dropped 40% year-to-date. This decline reflects ongoing market skepticism about its long-term viability and the challenges it faces in the competitive healthcare sector.
Recent Price Action
Appili Therapeutics Inc's stock has remained unchanged at C$0.01 this week, with no major fluctuations in price noted. Over the past month, the stock has also seen a lack of movement, contributing to a year-to-date decline of 40%. The trading volume has been relatively low, with the latest volume reported at 7,002 shares compared to a 20-day average of 52,058 shares, indicating a lack of investor interest.
Recent Company News
Advertisement
This week, Appili Therapeutics reported its fiscal year 2026 financial and operational results, which included the announcement of a US$40 million funding award from NIAID for its VXV-01 vaccine program. This funding is seen as a positive development, potentially aiding in the advancement of its vaccine pipeline. Additionally, the company disclosed the outcomes of its annual and special meeting of shareholders, where directors were elected for the upcoming year.
Technical Picture
From a technical standpoint, Appili's stock is trading below its 50-day moving average of C$0.02, which is a decline of 2.6%, and its 200-day moving average of C$0.02, down 26.5%. The stock has a 52-week range of C$0.01 to C$0.04, indicating it is currently at the lower end of this range. The beta of -0.21 suggests that the stock is less volatile compared to the broader market.
Insider Activity
No recent insider activity has been reported for Appili Therapeutics, which may indicate a period of stability or a lack of significant developments from company executives.
Price Action Summary
As of the last close, Appili Therapeutics Inc is priced at C$0.01, reflecting a 1D change of 0.00%. The stock's current situation presents a cautious outlook for investors as they await further developments in the company's operational and financial strategies.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
